Daiichi and AstraZeneca claim another breast cancer success, and further evidence of the ADC’s activity in very low HER2 expression.

A pipeline cull sees the US pharma joining AbbVie's exit, in the wake of Novartis’s big bet. 

Abstract titles reveal some of ASCO’s key datasets.